Kangxinuo Biological Co., Ltd. (hereinafter referred to as Kangxinuo Biological) was established in China in 2009. It is a leading high-tech biological products enterprise, whose mission is to provide solutions for the prevention and treatment of infectious diseases on a global scale, and to focus on the research, development, production and commercialization of innovative, high-quality and accessible vaccines for human use.
Kangxinuo Biological Co., Ltd. has a production system comparable to international quality standards and a research and development system with a global vision. Kangxinuo Biological Co., Ltd. was established in Tianjin, China on June 5438+10/October 65438+March, 2009, and is committed to the research and development of public health in China and the world. The company has four innovative vaccine platform technologies, including adenovirus vector vaccine technology, combination technology, protein design and recombination technology and preparation technology.
Inhalation of COVID-19 vaccine
This COVID-19 vaccine is the first inhalation vaccination of Kangxinuo. The principle is that the drug delivery equipment atomizes the vaccine into tiny droplets, which are inhaled into the lungs through the mouth, so that the atomized vaccine finally reaches the lungs through the respiratory tract, resulting in mucosal immunity that intramuscular injection vaccine does not have. The dosage used is one-fifth of the injection vaccine.